CDK 11 inhibition induces cytoplasmic p21 WAF 1 splice variant by p53 stabilisation and SF 3 B 1 inactivation
Molecular Oncology · 2026
DOI: 10.1002/1878-0261.70143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Radovan Krejcir und 12 weiteren Autor:innen. Beteiligte Einrichtung: RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase Inhibitor p21, Tumor Suppressor Protein p53, Alternative Splicing, RNA Splicing Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Czech Science Foundation, Ministry of Health of the Czech Republic, Vetenskapsrådet.
Abstract (Originalsprache)
CDK11 is a cyclin‐dependent kinase with a role in transcription and RNA splicing and represents a potential target for cancer treatment. We show that blocking CDK11 activity with the OTS964 inhibitor causes p53 stabilisation through MDM2 downregulation. Under these conditions, p53 activates the expression of its downstream effector CDKN1A (p21 WAF1 ), produced in two isoforms, the canonical p21 C and the recently described p21 L . We compared the ability of both isoforms to block proliferation and showed that p21 L partially lost its inhibitory potential, likely due to the missing cyclin‐binding Cy2 and PCNA‐interacting motifs and its cytoplasmic localisation. We identified the epitopes of four p21 WAF1 antibodies using phage display to determine isoform specificity. Moreover, we show that the trigger for p21 L induction is inhibition of the spliceosomal protein SF3B1. CDK11 activates SF3B1 by phosphorylation, and inhibition of either SF3B1 or CDK11 induces p21 L . We discovered an isoform similar to human p21 L in murine cells, suggesting evolutionary conservation of CDKN1A alternative splicing. Our results uncover an unknown link between RNA splicing and proliferation control involving a novel isoform of a key cell cycle inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
- National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Brno, Czech Republic.
- Laboratory of Growth Regulators, Institute of Experimental Botany, The Czech Academy of Sciences, Olomouc, Czech Republic.
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Solna, Sweden.
ORCID-Profile: Radovan Krejcir, Lukasz Arcimowicz
Förderung
- Czech Science Foundation
- Ministry of Health of the Czech Republic
- Vetenskapsrådet
- Ministry of Education, Youth and Sports of the Czech Republic
- European Social Fund Plus (ESF+), European Regional Development Fund (ERDF)
- Grantová Agentura České Republiky
- Ministerstvo Zdravotnictví Ceské Republiky
Zitieren
APA
Krejcir, R., Arcimowicz, L., Martinkova, L., Hrabal, V., Zavadil Kokas, F., Henek, T., Kucerikova, M., Bonczek, O., Zatloukalova, P., Hernychova, L., Coates, P. J., Vojtesek, B., & Lane, D. P. (2026). CDK 11 inhibition induces cytoplasmic p21 WAF 1 splice variant by p53 stabilisation and SF 3 B 1 inactivation. Molecular Oncology. https://doi.org/10.1002/1878-0261.70143
Vancouver
Krejcir R, Arcimowicz L, Martinkova L, Hrabal V, Zavadil Kokas F, Henek T, et al. CDK 11 inhibition induces cytoplasmic p21 WAF 1 splice variant by p53 stabilisation and SF 3 B 1 inactivation. Molecular Oncology. 2026. doi:10.1002/1878-0261.70143
BibTeX
@article{Krejcir2026,
author = {Krejcir, Radovan and Arcimowicz, Lukasz and Martinkova, Lucia and Hrabal, Vaclav and Zavadil Kokas, Filip and Henek, Tomas and Kucerikova, Martina and Bonczek, Ondrej and Zatloukalova, Pavlina and Hernychova, Lenka and Coates, Philip J and Vojtesek, Borivoj and Lane, David P},
title = {CDK 11 inhibition induces cytoplasmic p21 WAF 1 splice variant by p53 stabilisation and SF 3 B 1 inactivation},
journal = {Molecular Oncology},
year = {2026},
doi = {10.1002/1878-0261.70143}
}
EUVIMED